American Century Companies Inc. Sells 225,820 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

American Century Companies Inc. lowered its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 67.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 106,792 shares of the biopharmaceutical company's stock after selling 225,820 shares during the quarter. American Century Companies Inc. owned about 0.17% of Sage Therapeutics worth $580,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Picton Mahoney Asset Management increased its stake in shares of Sage Therapeutics by 126.0% in the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 3,581 shares in the last quarter. Ieq Capital LLC bought a new position in shares of Sage Therapeutics during the fourth quarter valued at approximately $57,000. US Bancorp DE lifted its holdings in shares of Sage Therapeutics by 22.3% during the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 2,268 shares during the last quarter. Teacher Retirement System of Texas boosted its position in shares of Sage Therapeutics by 21.6% in the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock worth $75,000 after purchasing an additional 2,446 shares in the last quarter. Finally, Empowered Funds LLC bought a new position in Sage Therapeutics during the 4th quarter valued at approximately $91,000. 99.22% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SAGE shares. HC Wainwright reissued a "neutral" rating and issued a $12.00 target price (down from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Wedbush reiterated a "neutral" rating and set a $6.00 price target on shares of Sage Therapeutics in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Scotiabank reduced their price objective on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a report on Wednesday, February 12th. Finally, Bank of America assumed coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They set an "underperform" rating and a $5.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Sage Therapeutics presently has an average rating of "Hold" and a consensus target price of $8.81.

Sage Therapeutics Stock Performance

NASDAQ:SAGE traded up $0.07 during trading hours on Thursday, reaching $7.44. The stock had a trading volume of 87,377 shares, compared to its average volume of 1,781,131. The company has a 50 day moving average price of $7.46 and a two-hundred day moving average price of $6.72. Sage Therapeutics, Inc. has a 52 week low of $4.62 and a 52 week high of $14.97. The stock has a market capitalization of $457.11 million, a PE ratio of -1.13 and a beta of 0.48.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Equities research analysts predict that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.